The I-SPY COVID test uses Quantum Leap Healthcare Collaborative’s adaptive platform test design to increase test effectiveness by minimizing the number of participants and the time required to compare possible treatments.
“Collaborative study efforts leveraging adaptive platform trials enable faster and more comprehensive learning of what works for patients, and are especially critical to addressing urgent physical fitness threats like COVID-19,” said Dr. Mark McClellan, director of Robert J. Margolis, Duke University Health Policy Center and former U.S. FDA commissioner and administrator of the U.S. Medicare and Medicaid. “Platform testing lowers prices and increases the ease of well-supported studies, especially when you want to quickly compare several prospective remedies. The I-SPY COVID trial extends an immediate and effective platform testing strategy to compare promising remedies while maintaining an adequate point of protection and statistical rigor required for regulatory evaluation.”
Check the content to download the multimedia content: https://www.prnewswire.com/news-releases/members-of-the-covid-rd-alliance-and-quantum-leap-healthcare-collaborative-enroll-first-patients -en -i-spy-covid-trial-301104431.html
Quantum Leap Healthcare COLLABORATIVE SOURCE